Skip to content
    FDA & Regulatory

    FDA Approves Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer

    FDAFDA What's New: Drugs

    FDA Approves Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
    The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin. This regulatory approval designates the combination regimen for the adjuvant treatment of adult and pediatric patients aged two years and older diagnosed with Stage III mismatch repair deficient (dMMR) colon cancer.

    Key Takeaways

    • The FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with Stage III mismatch repair deficient (dMMR) colon cancer.
    Read the original sourceFDA What's New: Drugs